All In Biotech

Drug Trial Radar · NCT07702656

A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Sep 30, 2028

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of SYS6026 at different doses compared to placebo in treating patients with HPV16 or 18-related high-grade cervical squamous intraepithelial lesions (HSIL).

Conditions

  • High-grade Cervical Intraepithelial Lesions

Interventions

  • SYS6026Biological

    Administration continued until D168

  • PlaceboBiological

    Administration continued until D168

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants whose pathology had resolved/remission to CIN1 and HPV16/18 negative at 36 weeks post-vaccination (independent pathology review)Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CSPC Megalith Biopharmaceutical Co., Ltd.

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.